Ownership history in UBS Group AG · 39 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in ADAPTIMMUNE THERAPEUTICS PLC (ADAP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 6,667,358 | +6,604,400 | +10490.2% | 0.00% | $867K | — |
| 2025 Q2 | REDUCED | 62,958 | -949,782 | -93.8% | 0.00% | $15K | — |
| 2025 Q1 | ADDED | 1,012,740 | +870,996 | +614.5% | 0.00% | $200K | — |
| 2024 Q4 | ADDED | 141,744 | +139,927 | +7701.0% | 0.00% | $76K | — |
As of 2025 Q4 — sorted by position size